Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

  • P. Sarzi- Puttini | office@pagepress.org
  • M. Antivalle
  • A. Marchesoni
  • E.G. Favalli
  • R. Gorla
  • M. Filippini
  • R. Caporali
  • F. Bobbio-Pallavicini
  • C. Montecucco
  • F. Atzeni

Abstract

Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 1534

  • PDF: 769
How to Cite
Sarzi- Puttini, P., Antivalle, M., Marchesoni, A., Favalli, E., Gorla, R., Filippini, M., Caporali, R., Bobbio-Pallavicini, F., Montecucco, C., & Atzeni, F. (1). Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo, 60(4), 290-295. https://doi.org/10.4081/reumatismo.2008.290

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>